The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple ...
Among patients with relapsed or refractory multiple myeloma, Tecvayli (teclistamab-cqyv) monotherapy was associated with a 71 ...
Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...
Arcellx (ACLX) and Legend Biotech (LEGN) traded higher on Tuesday after the U.S. FDA issued draft guidance on the use of ...
The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...
Patients were randomly assigned on a 1:1 basis to receive teclistamab as monotherapy or physician’s choice of ...
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...
Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A third of patients with relapsed/refractory multiple myeloma ...
Please provide your email address to receive an email when new articles are posted on . A triplet regimen extended OS compared with the current standard of care for patients with relapsed or ...
The FDA expanded the labels of two CAR T-cell products for multiple myeloma, allowing their use in earlier lines of treatment for relapsed or refractory disease. Ciltacabtagene autoleucel (cilta-cel; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results